| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_52abd0d8b9782a9ed5f4ae79b89bccb8 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-13043
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-03
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-33 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70521
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0636
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-5437
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-1007 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 |
| filingDate |
2015-12-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bb9ab7067d6f10ee280aef10ba9a14c2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_80b4c31059a0233e1db02eb14cc75ce1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4ab274650fd297e269822e80264167c8 |
| publicationDate |
2018-02-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-107709353-A |
| titleOfInvention |
Methods and compositions for treating cancer |
| abstract |
Described herein are compositions and methods involving immune cells expressing chimeric antigen receptors and O6 - methylguanine DNA methyltransferase (MGMT) proteins that bind IL13 receptor alpha-2 (IL13Rα2) Both. Viral particles comprising IL13 chimeric antigen receptor (IL13CAR) or its variants and MGMT protein or its variants are used to transfect immune cells such as T cells, confer IL13Rα2 targeting activity to the transfected cells and resist chemotherapy resistance to the drug temozolomide (TMZ). The compositions and methods described herein are useful in cancer therapy, such as the treatment of high-grade glioma. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108440674-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113304267-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113304267-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114014941-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110157674-A |
| priorityDate |
2014-12-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |